A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis (NCT05995964)
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied. PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage. The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective. Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).
Who can join: Review the eligibility criteria below.
Location: Allervie Clinical Research — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (98 Sites)
Showing the first 25 of 98 sites.
- Allervie Clinical Research — Birmingham, Alabama
- Onyx Clinical Research - Peoria — Peoria, Arizona
- Medical Dermatology Specialists — Phoenix, Arizona
- Onyx Clinical Research — Phoenix, Arizona
- Banner - University Medicine Dermatology Clinic — Tucson, Arizona
- Marvel Clinical Research — Huntington Beach, California
- California Allergy and Asthma Medical Group — Los Angeles, California
- University Dermatology Trials, INC. — Newport Beach, California
- Northridge Clinical Trials — Northridge, California
- Profound Research LLC — Oceanside, California
- Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc. — San Diego, California
- West Dermatology La Jolla — San Diego, California
- Sunwise Clinical Research — Walnut Creek, California
- AboutSkin Research, LLC — Greenwood Village, Colorado
- Renaissance Research and Medical Group — Cape Coral, Florida
- Florida International Medical Research — Coral Gables, Florida
- Revival Research — Doral, Florida
- St. Jude Clinical Research — Doral, Florida
- SouthCoast Research Center — Miami, Florida
- Floridian Research Institute Llc — Miami, Florida
- Global Health Research Center, Inc. — Miami Lakes, Florida
- Ziaderm Research LLC — North Miami Beach, Florida
- Clinical Neuroscience Solutions, Inc. — Orlando, Florida
- GCP Research, Global Clinical professionals — St. Petersburg, Florida
- ForCare Clinical Research — Tampa, Florida
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.